Purple Biotech Ltd. (PPBT)
2.73
0.06 (2.16%)
At close: Apr 24, 2025, 3:59 PM
2.70
-1.10%
After-hours: Apr 24, 2025, 06:34 PM EDT
2.16% (1D)
| Bid | 2.54 |
| Market Cap | 37.27K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.24M |
| EPS (ttm) | -49.9 |
| PE Ratio (ttm) | -0.05 |
| Forward PE | -1.49 |
| Analyst | Buy |
| Ask | 3 |
| Volume | 7,448 |
| Avg. Volume (20D) | 17,313 |
| Open | 2.80 |
| Previous Close | 2.67 |
| Day's Range | 2.70 - 2.94 |
| 52-Week Range | 2.00 - 20.60 |
| Beta | -0.11 |
About PPBT
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and panc...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 20, 2015
Employees 9
Stock Exchange NASDAQ
Ticker Symbol PPBT
Website https://purple-biotech.com
Analyst Forecast
According to 1 analyst ratings, the average rating for PPBT stock is "Buy." The 12-month stock price forecast is $33, which is an increase of 1108.79% from the latest price.
Stock Forecasts2 months ago
+3.87%
Purple Biotech shares are trading higher after the...
Unlock content with
Pro Subscription
2 months ago
+3.87%
Purple Biotech Advances NT219 Into a Phase 2 Study In Head And Neck Cancer
